bullish

Chugai Pharmaceutical (4519 JP): Export Drives Growth; New Products To Relieve Domestic Market Pain

170 Views29 Oct 2024 22:56
​Chugai reported 45% growth in overseas sales in 3Q24, driven by Hemlibra. The company raised 2024 guidance, which calls for revenue and core operating profit growth of 3% and 20%, YoY, respectively.
What is covered in the Full Insight:
  • Financial Performance Overview
  • Upward Revision of 2024 Guidance
  • Hemlibra's Market Momentum
  • Challenges in Domestic Market
  • Outlook and Valuation
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
x